CoChat

Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

Open access
Amrein, Philip C., Attar, Eyal C., Takvorian, Tak, Hochberg, Ephraim P., Ballen, Karen K., Leahy, Kathleen M., Fisher, David C., LaCasce, Ann S., Jacobsen, Eric D., Armand, Philippe, Hasserjian, Robert P., Werner, Lillian, Neuberg, Donna, Brown, Jennifer R. · 2011 · Clinical Cancer Research
Cited by 122

The DOI matches its Crossref record.

Abstract

Purpose: Chronic lymphocytic leukemia (CLL) cells treated with dasatinib in vitro undergo apoptosis via inhibition of Lyn kinase. Thus, in this study we tested the activity of dasatinib in patients with relapsed CLL. Experimental Design: Patients were eligible for this phase II trial if they had documented CLL/SLL and had failed at least 1 prior therapy with a fludarabine-containing regimen and if they required therapy according to NCI-WG criteria. The starting dose of dasatinib was 140 mg daily. Results: Fifteen patients were enrolled, with a median age of 59 and a median of 3 prior regimens. All patients had received fludarabine, and 5 were fludarabine-refractory. Eleven of the 15 (73%) had high risk del(11q) or del(17p) cytogenetics. The primary toxicity was myelosuppression, with grade 3 or 4 neutropenia and thrombocytopenia in 10 and 6 patients, respectively. Partial responses by NCI-WG criteria were achieved in 3 of the 15 patients (20%; 90% CI: 6–44). Among the remaining 12 patients, 5 had nodal responses by physical exam, and 1 patient had a nodal and lymphocyte response but with severe myelosuppression. Pharmacodynamic studies indicated apoptosis in peripheral blood CLL cells within 3 to 6 hours after dasatinib administration, associated with downregulation of Syk (spleen tyrosine kinase) mRNA. Conclusions: Dasatinib as a single agent has activity in relapsed and refractory CLL. Clin Cancer Res; 17(9); 2977–86. ©2011 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-10-2879

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 122

Metadata

Authors
Amrein, P. C., Attar, E. C., Takvorian, T., Hochberg, E. P., Ballen, K. K., Leahy, K. M., Fisher, D. C., LaCasce, A. S., Jacobsen, E. D., Armand, P., Hasserjian, R. P., Werner, L., Neuberg, D., & Brown, J. R.
Venue
Clinical Cancer Research
Published
2011-05-01
Volume
17
Issue
9
Pages
2977-2986
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2168215118
Cited by
122
References
0
FWCI
10.54
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-10-2879
The paper
Amrein, P. C., Attar, E. C., Takvorian, T., Hochberg, E. P., Ballen, K. K., Leahy, K. M., Fisher, D. C., LaCasce, A. S., Jacobsen, E. D., Armand, P., Hasserjian, R. P., Werner, L., Neuberg, D., & Brown, J. R. (2011). Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-10-2879

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.